Updated Results for Small-Molecule Drug in Phase I/II Trial Show Strong Promise

Ariad Pharmaceuticals (based in Cambridge, MA and Lausanne, Switzerland) updated results for brigatinib, a small-molecule drug that targets a specific gene in a range of cancers, including non-small cell lung cancer. The survival rate of patients in the trials has been very promising.

http://labiotech.eu/very-promising-results-for-resistant-lung-cancer/